Abu Dhabi, UAE – WAM The Abu Dhabi Biobank Initiative, a joint strategic project between the Department of Health – Abu Dhabi and “M42”, signed a strategic agreement with Human Life Cord – Japan. With the aim of localizing the development and application of stem cell therapies extracted from umbilical cord blood in Abu Dhabi. To enhance access to stem cell therapies in the UAE and the Middle East and North Africa region. The emirate’s status is supported by a global center for advanced healthcare, life sciences and precision medicine.
The collaboration combines Abu Dhabi Biobank’s infrastructure with Human Life Cord’s MSC technology platform. To accelerate the development of regenerative therapies tailored to the region’s needs and address priority health challenges.
Supporting innovative research
The agreement also highlights the role of the Department of Health – Abu Dhabi in supporting innovative research and expanding access to life-saving treatments. Through public storage services for umbilical cord blood and supervision of associated operational processes.
The two parties intend to establish one of the first local manufacturing pathways for stem cell treatments extracted from the umbilical cord in the UAE in accordance with good manufacturing practices and clinical application. Supporting the integrated development chain from the availability of biological samples to clinical application. It enhances regional resilience in this vital area.
